ReviewExpert opinion on drug discovery2015
Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.
Review in Expert opinion on drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Transcriptome profiles associated with resilience and susceptibility to single prolonged stress in the locus coeruleus and nucleus accumbens in male sprague-dawley rats.Behavioural brain research · 2023Article
- Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?International journal of molecular sciences · 2020Review
- Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.Current neuropharmacology · 2020Review
- Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system.Neurobiology of stress · 2019Review
- Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions.Molecules (Basel, Switzerland) · 2019Review
- Noradrenergic depletion causes sex specific alterations in the endocannabinoid system in the Murine prefrontal cortex.Neurobiology of stress · 2019Article
- The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System.Biological psychiatry · 2018Article
- Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.ACS chemical neuroscience · 2018Review
- Sex differences in the effect of cannabinoid type 1 receptor deletion on locus coeruleus-norepinephrine neurons and corticotropin releasing factor-mediated responses.The European journal of neuroscience · 2018Article
- Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.Progress in neuro-psychopharmacology & biological psychiatry · 2018Review
- Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice.Molecular psychiatry · 2017Article
- Co-localization of the cannabinoid type 1 receptor with corticotropin-releasing factor-containing afferents in the noradrenergic nucleus locus coeruleus: implications for the cognitive limb of the stress response.Brain structure & function · 2017Article
- Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.Experimental neurology · 2017Article
- Acute cortisol reactivity attenuates engagement of fronto-parietal and striatal regions during emotion processing in negative mood disorders.Psychoneuroendocrinology · 2016Article
- Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?Psychopharmacology · 2016Review
- Endocannabinoid Mediates Excitatory Synaptic Function of β-Neurexins. Commentary: β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling.Frontiers in neuroscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe endocannabinoid (eCB) system plays an important role in the control of mood, and its dysregulation has been implicated in several psychiatric disorders. Targeting the eCB system appears to represent an attractive and novel approach to the treatment of depression and other mood disorders. However, several failed clinical trials have diminished enthusiasm for the continued development of eCB-targeted therapeutics for psychiatric disorders, despite the encouraging preclinical data and promising preliminary results obtained with the synthetic cannabinoid nabilone for treating post-traumatic stress disorder. AREAS COVERED: This review describes the eCB system's role in modulating cell signaling within the brain. There is a specific focus on eCB's regulation of monoamine neurotransmission and the stress axis, as well as how dysfunction of this interaction can contribute to the development of psychiatric disorders. Additionally, the review provides discussion on compounds and drugs that target this system and might prove to be successful for the treatment of mood-related psychiatric disorders. EXPERT OPINION: The discovery of increasingly selective modulators of CB receptors should enable the identification of optimal therapeutic strategies. It should also maximize the likelihood of developing safe and effective treatments for debilitating psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.